Clinical Trials Browser

Active not recruiting × Ovarian Neoplasms × durvalumab × Clear all

NCT02264678 2026-05-12

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Phase 1 Active not recruiting

Ovarian Neoplasms

NCT02734004 2026-04-20

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT04742075 2026-02-27

DOVACC

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03737643 2025-01-29

DUO-O

Phase 3 Active not recruiting

1,407 enrolled 1 FDA

Ovarian Neoplasms